RankingsPricing
  1. US-listed companies
  2. Viridian Therapeutics, Inc.\DE
  3. Raw

Viridian Therapeutics, Inc.\DEVRDN

Market cap
$2.6B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss-8-11-13-27-33-42-111-79-130-238-270
Issuance of common stock under license agreement-0----68-6-
Share-based compensation expense432244414206742
Amortization of Debt Issuance Costs and Discounts--------000
Depreciation and amortization00000000011
Accretion and amortization of premiums and discounts on available-for-sale securities----00-0-101116
Net loss on extinguishment of debt---71,000-------0-
Debt Extinguishment Expense---------1-
Loss on sale of equipment--------0--0-0
Non-Cash Lease Expense--------0000
Other non cash items-------0---0-
Prepaid expenses and other assets-0-0-01-0-0013212
Accounts payable----0-01-0212-12-0
Accrued and other liabilities----211518522
Unbilled revenue---------0--0
Deferred revenue-------1-0-0-0
Net cash used in operating activities-2-7-7-28-27-36-30-55-94-184-232
Purchases of short-term investments-------188223408695
Proceeds from sales and maturities of short-term investments--------109315467
Purchases of property and equipment00000000111
Net cash used in investing activities-0-0-01-3028-50-74-115-94-229
Proceeds from Issuance of Common Stock---------1568
Proceeds from Issuance of Private Placement---------76-
Common Stock------1719725
Preferred Stock------51352
Payment of issuance costs-----0-----
Proceeds from Issuance of Convertible Preferred Stock------91-44-25
Proceeds from Issuance of Warrants------251---
Payment of debt extinguishment costs---------1-
Payment of debt issuance costs--------0--
Proceeds from Stock Options Exercised---000-13195
Proceeds from Stock Plans-------0011
Net cash provided by financing activities713-052420101125322226458
Net increase (decrease) in cash and cash equivalents------821-4113-53-3
Interest paid----010-012
Capital Expenditures Incurred but Not yet Paid-------00-0
Stock Issuance Costs Included In Accrued Liabilities---------00
Stock Issuance Costs Included In Accounts Payable---------0-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability----------0
Remeasurement of operating lease right-of-use assets for lease modifications----------1
Notes Reduction---------5-
Notes Issued---------5-
Amortization Of Stock Issuance Costs------000--